dMed Biopharmaceutical Co., Ltd., a Shangai, China-based full service Clinical Contract Research Organization (CRO), completed a nearly US$50m Series B financing.
The round was led by Vivo Capital with participation from Legend Capital, Qiming Venture Partners and Lilly Asia Ventures.
The company intends to use the funds to accelerate expansion of its clinical operations and information technology infrastructure, while extending its global capacity in clinical development and product registration.
As a global “next generation” full service clinical contract research organization, dMed aims to tap the trend with its strong capacity to file new drug applications and conduct research simultaneously in China, the United States and Europe. Since its launch three years ago, dMed has attracted industry elites and well-known experts in both China and the US to join the company. It has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and currently employs more than 600 professionals globally. dMed completed the acquisition of Target Health, a full service New York-based CRO, in the middle of this year to extend its global footprint and add new technologies to its global service offering.
Led by Dr. Lingshi Tan, Founder and CEO, dMed is a full service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe to effectively raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rates.
The business covers consulting, early development & clinical pharmacology, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, clinical science & medical affairs, quality assurance, regulatory affairs and strategy.
dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs more than 600 professionals globally.